Biomea Fusion, Inc. (BMEA)

Pharmaceutical Preparations · market cap $100M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-03 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Biomea Fusion (BMEA) is a clinical-stage pharmaceutical company with a single disclosed pipeline asset, BMF-219, currently in Phase 2 development for Type 2 Diabetes Mellitus. The company carries a ~$96M market cap against $44.7M in cash, implying roughly 11.5 months of runway and an enterprise value near $51M. Mechanism of action for BMF-219 is not disclosed in available facts.

The catalyst path

2026-11-03 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
BMF-219	Phase 2	Type 2 Diabetes Mellitus

Price & technical context

3-month

-6.4%

6-month

-11.4%

12-month

-34.7%

52-wk range

$0.96–$2.67

vs 50-day MA

-11.9%

vs 200-day MA

-6.8%

Realized vol

92.9%

Max drawdown

-92.3%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for BMEA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.